A.L.S. Drug Relyvrio Will Be Taken Off the Market, Its Maker Says
Results of a large clinical trial found the treatment did not work any better than a placebo.
Posted inConflicts of Interest Depression (Mental) Drugs (Pharmaceuticals) Ethics and Official Misconduct Johns Hopkins Hospital (Baltimore, Md) Leary, Timothy Nineteen Hundred Sixties Placebos Psychedelic and Hallucinogenic Drugs Psychology and Psychologists Religion and Belief Research Suicides and Suicide Attempts
The Psychedelic Evangelist
A Johns Hopkins scientist was known for rigorous studies of psychedelics. Was he a true believer?
Posted inComputers and the Internet Cyberattacks and Hackers Doctors Drugs (Pharmaceuticals) Drugstores Federal Bureau of Investigation Health and Human Services Department Health Insurance and Managed Care Hospitals Medicare UnitedHealth Group Inc
With Cyberattack Fix Weeks Away, Health Providers Slam United
Hospitals, doctors and clinics expressed frustration that they will have to wait even longer for reimbursements after hackers paralyzed the largest U.S. billing clearinghouse.
Posted inClinical Trials Cohen, Joshua B Drugs (Pharmaceuticals) Food and Drug Administration Klee, Justin United States
A.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the Market
Leaders of the treatment’s manufacturer, Amylyx, said they would announce their plans for it within eight weeks.